StockpollyBeta
Get App
Delisting riskPopularity #4,472
ASBP · NASDAQ · Biotechnology

Aspire Biopharma (ASBP)

Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.

$8.20
After-hours close−0.01 (−0.17%)
At close$8.21(−5.80%)

  1. Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

    AccesswireBuyback

  2. Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

    Accesswire

  3. Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?

    Defense World

  4. Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

    GlobeNewsWire

  5. Aspire Biopharma Stock Is Sliding Today: What's Going On?

    Benzinga

  6. Aspire Biopharma Issues Shareholder Letter

    Accesswire

  7. Aspire Biopharma Announces $5.0 Million Share Repurchase Program

    Accesswire

  8. Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

    Accesswire

  9. Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

    Accesswire

  10. Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

    Accesswire

  11. Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

    Accesswire

  12. Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

    Accesswire

  13. Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

    Accesswire

  14. Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

    Accesswire

  15. Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

    Accesswire

  16. Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Decrease in Short Interest

    Defense World

  17. Aspire Biopharma Announces Reverse Stock Split

    Accesswire

  18. Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

    Accesswire

  19. Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

    Accesswire

  20. Aspire Biopharma Provides Q3 2025 Business Update

    Accesswire